CommentFDA draft guidance and health-outcomes research
References (7)
- et al.
Symptom recording in a randomized clinical trial: paper diaries vs electronic or telephone data capture
Control Clin Trials
(2004) Draft guidance for industry on patient-reported outcome measures: use in medicinal product development to support labeling claims
Fed Register
(2006)Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products
There are more references available in the full text version of this article.
Cited by (79)
Patient involvement in regulation: an unvalued imperative
2021, The LancetEvaluating response in gastroparesis: Patient reported outcome measures and survey instruments
2020, Gastroparesis: Pathophysiology, Clinical Presentation, Diagnosis and TreatmentHow to decide which patient-reported outcome measure to use? A practical guide for plastic surgeons
2018, Journal of Plastic, Reconstructive and Aesthetic SurgeryCitation Excerpt :It is important that we have patient-reported data to advocate certain treatments for patients, especially in the current climate where rationing of procedures is occurring. Many regulatory bodies also demand the inclusion of patient-reported data in applications.10 The drive for value-based healthcare requires the wider adoption of PROMs to measure health outcomes across different providers and healthcare settings,11,12 and the King's Fund report suggests that PROMs are likely to become “a key part of how health care is funded, provided and managed”.2
Ceramic biomaterials for tissue engineering
2018, Fundamental Biomaterials: Ceramics
Copyright © 2007 Elsevier Ltd. All rights reserved.